CD19-directed T cell-engaging antibodies for the treatment of autoimmune disease
- PMID: 38587494
- PMCID: PMC11001598
- DOI: 10.1084/jem.20240499
CD19-directed T cell-engaging antibodies for the treatment of autoimmune disease
Abstract
Jennifer S. Michaelson, Chief Scientific Officer at Cullinan Oncology, and Patrick A. Baeuerle, scientific advisor to Cullinan Oncology and honorary professor in immunology at Ludwig Maximilians University Munich, discuss the use of CD19-specific T cell-engaging antibody therapies (TCEs) as therapeutics for autoimmune diseases.
© 2024 Michaelson and Baeuerle.
References
-
- Arnold, C. 2024. Nat. Med. 10.1038/s41591-023-02716-7 - DOI
-
- Clatworthy, M.R. 2011. Am. J. Transpl. 10.1111/j.1600-6143.2011.03554.x - DOI
-
- Falchi, L., et al. . 2023. Blood. 10.1182/blood.2021011994 - DOI
-
- Finck, A.V., et al. . 2022. Nat. Med. 10.1038/s41591-022-01765-8 - DOI
-
- Gaballa, S., et al. . 2023. Blood. 10.1182/blood-2023-174668 - DOI
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
